Rx Product Updates (April 2016)

Contemporary ClinicApril 2016
Volume 2
Issue 2

Read about the new Rx products featured in April 2016.


Indication:Nucala (mepolizumab), an interleukin-5 antagonist monoclonal antibody, is an add-on maintenance treatment for patients 12 years or older with severe asthma and an eosinophilic phenotype. The recommended dosage is 100 mg subcutaneously once every 4 weeks.

Dosage Form:Injection: 100 mg of lyophilized powder in a single-dose vial for reconstitution

For More Information:gsksource.com

SPIRIVA RESPIMATMarketed by:Boehringer Ingelheim Pharmaceuticals, Inc

Indication:The FDA expanded the use of Spiriva Respimat (tiotropium bromide inhalation spray) to include long-term, once-daily maintenance treatment of asthma in patients 12 years and older. The recommended dosage for this indication is 2 inhalations of 1.25 mcg once daily.

Dosage Form:Inhalation spray: 1.25 mcg tiotropium per actuation with the Spiriva Respimat inhaler; 2 actuations equal 1 dose (2.5 mcg)

For More Information:spiriva.com

BREO ELLIPTAMarketed by:GlaxoSmithKline and Theravance, Inc.

Indication:The FDA expanded the indication of Breo Ellipta (fluticasone furoate/ vilanterol), approving it for the once-daily treatment of asthma in patients 18 years and older. The recommended dose is 1 inhalation of Breo Ellipta 100 mcg/25 mcg or 200 mcg/25 mcg once daily. Breo Ellipta previously received FDA approval for long-term maintenance treatment of airflow obstruction and for reducing exacerbations in patients with chronic obstructive pulmonary disease.

Dosage Form:Inhalation powder (fluticasone furoate/vilanterol): 100 mcg/25 mcg or 200 mcg/25 mcg

For More Information:gsksource.com/ pharma/content/gsk/source/us/en/ brands/breo.html

Related Content
© 2024 MJH Life Sciences

All rights reserved.